Wednesday August 5, 2026 4:05 PM ET

Caris Life Sciences Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance

Thursday July 16, 2026 8:30 AM ET

Caris Life Sciences to Report Second Quarter 2026 Financial Results on August 5, 2026

Tuesday July 14, 2026 8:30 AM ET

Caris Life Sciences Expands Precision Oncology in Metastatic Prostate Cancer with PTEN IHC Testing

Wednesday July 1, 2026 8:30 AM ET

Caris Life Sciences Launches Caris Detect, the World's Most Sensitive and Comprehensive Multi-Cancer Early Detection Blood Test

Tuesday June 16, 2026 8:30 AM ET

Caris Life Sciences Announces Dual Listing on NYSE Texas

Monday June 8, 2026 8:30 AM ET

Caris Life Sciences Announces Share Repurchase Program

Tuesday May 26, 2026 8:30 AM ET

Caris Life Sciences Launches Behind the Diagnosis Campaign Spotlighting Patient Lives Transformed by Caris' Comprehensive Genomic Testing

Friday May 15, 2026 8:30 AM ET

Caris Life Sciences Publishes Study on the Caris Lookback Program Demonstrating the Ongoing Clinical Value of Comprehensive Testing with Caris MI Cancer Seek

Monday May 11, 2026 12:15 PM ET

Caris Life Sciences Publishes Study Showing Whole Exome Measurement of Tumor Mutational Burden Results in Increased Overall Survival Compared to Estimates from Targeted Gene Panels

Friday May 8, 2026 4:05 PM ET

Caris Life Sciences Submits Application to New York State Department of Health for Caris Assure Blood-Based Testing Authorization

Thursday May 7, 2026 4:05 PM ET

Caris Life Sciences Reports First Quarter 2026 Financial Results

Tuesday May 5, 2026 8:30 AM ET

Caris Life Sciences Launches Caris MI Clarity, the First and Only AI-Powered Test to Predict Both Early and Late Distant Recurrence Risk in Breast Cancer at the Time of Diagnosis

Monday May 4, 2026 8:30 AM ET

Caris Life Sciences Receives MolDX Approval for Caris ChromoSeq, Advancing Access to Comprehensive Genomic Profiling for Myeloid Malignancies

Wednesday April 29, 2026 8:30 AM ET

Caris Life Sciences Publishes Study Validating Caris AI Insights for Temozolomide Benefit in Glioblastoma Patients

Friday April 24, 2026 8:30 AM ET

Caris Life Sciences to Present at the BofA Securities 2026 Health Care Conference and the Goldman Sachs 47th Annual Global Healthcare Conference

Monday April 20, 2026 8:30 AM ET

Caris Life Sciences to Report First Quarter 2026 Financial Results on May 7, 2026

Friday April 17, 2026 8:30 AM ET

Caris Precision Oncology Alliance Welcomes UCSF Helen Diller Family Comprehensive Cancer Center

Wednesday April 15, 2026 8:30 AM ET

Caris Life Sciences Right-In-Time Clinical Trial Solution Expands Access to Precision Oncology Trials for Historically Underserved Cancer Patients

Wednesday April 8, 2026 8:30 AM ET

Caris Life Sciences Introduces Multimodal AI-Powered Molecular Insight to Identify the Benefit or Harm from the Addition of Chemotherapy for NSCLC Patients

Thursday April 2, 2026 8:30 AM ET

Caris Life Sciences Announces Launch of Caris ChromoSeq, the World's First Whole Genome and Whole Transcriptome Tumor Profiling Assay for Myeloid Malignancies

Tuesday March 31, 2026 6:00 PM ET

Caris Life Sciences Finalizes Achieve 1 Study Results Reinforcing the Superior Sensitivity and Specificity of Caris Detect

Thursday March 26, 2026 8:30 AM ET

Caris Life Sciences Advances Precision Oncology with New AI Insights Predicting Brain Metastases Risk in Breast and Lung Cancer

Wednesday March 25, 2026 8:30 AM ET

Caris Life Sciences to Present Six Oncology Studies Utilizing Proprietary Multimodal Data at the AACR Annual Meeting 2026

Tuesday March 24, 2026 8:30 AM ET

Caris Life Sciences Highlights the Importance of DPYD Testing in Colorectal Cancer During Colorectal Cancer Awareness Month

Monday March 16, 2026 8:30 AM ET

Caris Life Sciences Introduces Powerful New Caris AI Insights to Identify Early Platinum Resistance in Ovarian Cancer

Wednesday March 11, 2026 8:30 AM ET

Caris Life Sciences to Showcase Five Studies at the 2026 USCAP Annual Meeting

Monday March 9, 2026 8:30 AM ET

Caris Life Sciences Launches a Novel Caris AI Insights Signature to Guide First-Line Therapy Selection and Treatment De-Escalation in Pancreatic Cancer

Thursday February 26, 2026 4:05 PM ET

Caris Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook

Tuesday February 24, 2026 8:30 AM ET

Caris Launches Proprietary AI Insights Signature Which Deepens Understanding of Response to Breast Cancer Patients' Oral Chemotherapy Drug